期刊文献+

血浆B型脑利钠肽指导心衰患者袢利尿剂的使用对于肾功能的作用观察 被引量:11

Usage of loop diuretics based on serum BNP level in patients with heart failure contributes to renal function protection
暂未订购
导出
摘要 目的:了解血浆B型脑利钠肽(BNP)指导袢利尿剂的使用是否有利于心衰患者肾功能的保护。方法:100例入选患者随机分为两组,袢利尿剂的使用分别依据NYHA心功能分级加测量体重(N+W组)及血浆BNP浓度加测量体重(B+W组)。定期测量血肌酐、血中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、血浆BNP,并进行动态观察、分析。结果:基线时两组血浆BNP、肌酐浓度及NGAL浓度比较,P值分别为0.122、0.08、0.082。以最低有效剂量维持时N+W组血浆BNP、肌酐浓度及NGAL浓度均高于B+W组,P值分别为0.042、0.036、0.025。维持治疗1个月后N+W组血浆BNP、肌酐浓度及NGAL浓度均高于B+W组,P值分别为<0.001、0.02、<0.001。基线至最低有效剂量维持治疗前N+W组8例心衰复发,B+W组10例心衰反复发作,P=0.795;维持治疗1个月内N+W组9例心衰复发,B+W组1例心衰复发,P=0.016。结论:血浆BNP指导袢利尿剂的使用可以减少心衰复发,更有利于心衰患者肾功能的保护。 Objective This study is aimed to investigate whether usage of loop diuretics, according to serum BNP level, in patients with heart failure is more useful for renal function protection. Method One hundred patients with heart failure were randomly divided into two groups. The diuretics usage is based on the NYHA classification plus measuring of weight (N + W), or plasma BNP level plus measuring of weight (B + W), respectively. Serum creatinine (CR), blood neutrophils gelatin enzyme related lipid carrier protein (NGAL) and plasma B-type brain natriuretic peptide (BNP) were regularly measured and analyzed dynamically. Result At baseline, the plasma level of BNP, creatinine and NGAL had no difference between two groups (P = 0.122, 0.08 and 0.082 respectively). After giving the minimum effective dose, the plasma level of BNP, creatinine and NGAL in group (N + W) was higher than that in group (B + W) (P = 0.042, 0.036 and 0.025 respectively). After one- month maintenance therapy, the plasma level of BNP, creatinine and NGAL in group (N + W) was much higher than that in group (B + W) (P 〈 0.001, P = 0.02 and P 〈 0.001 respectively). From baseline to the minimum effective dose, eight patients experienced recurrence of heart failure in group (N + W), 10 in group (B + W) (P = 0.795) ; After one month maintenance therapy, 9 patients experienced recurrence of heart failure in group (N+W), only 1 in group (B + W) (P = 0.016). Conclusion According to serum BNP level, loop diuretics usage in patients with heart failure could reduce the recurrence of heart failure, and could be more conducive for renal function protection.
出处 《实用医学杂志》 CAS 北大核心 2013年第5期743-745,共3页 The Journal of Practical Medicine
基金 佛山市卫生局医学科研计划课题(编号:20122202)
关键词 B型脑利钠肽 袢利尿剂 心力衰竭 BNP loop diuretics heart failure
  • 相关文献

参考文献10

  • 1Morrissey R P, Czer L, Shah P K. Chronic heart failure: current evidence, challenges to therapy, and future directions [J]. Am J Cardiovasc Drugs, 2011,11 (3):153-171.
  • 2Howlett J G. Acute heart failure: lessons learned so far[J]. Can J Cardiol, 2011,27 (3) : 284-295.
  • 3Damman K, Ng Kam Chuen M J, MacFadyen R J, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function [J]. J Am Coll Cardiol, 2011,57(22) :2233-2241.
  • 4Peacock W F, Costanzo M R, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry [J]. Cardiology, 2009,113( 1 ) : 12-19.
  • 5West R, Liang L, Fonarow G C, et al. Characterization of heart failure patients with preserved ejection fraction: A comparison between ADHERE-US registry and ADHERE- International registry [J]. Eur J Heart Fail, 2011,13(9) : 945 -952.
  • 6Aziz E F, Alviar C L, Herzog E, et al. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompensated heart failure is less nephrotoxic and carries a lower readmission at thirty days [J]. Hellenic J Cardiol, 2011,52(3) : 227-235.
  • 7魏勇,欧阳平.慢性心力衰竭患者利尿剂抵抗的研究现状[J].中华内科杂志,2010,49(6):525-527. 被引量:52
  • 8Costanzo M R, Johannes R S, Pine M, et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure : a propensity score and instrumental variable analysis using the Acutely Decomp-ensated Heart Failure National Regisuy (ADHERE) database [J]. Am Heart J, 2007,154(2) :267-277.
  • 9Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next [J]? Circulation, 2002,105 (20) : 2392-2397.
  • 10Fonarow G C, Peacock W F, Horwich T B, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE [J]. Am J Cardiol, 2008,101 (2) : 231-237.

二级参考文献10

  • 1Kittleson M,Hurwitz S,Shah MR,et al.Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality.J Am Coll Cardiol,2003,41:2029-2035.
  • 2De Bruyne LK.Mechanisms and management of diuretic resistance in congestive heart failure.Postgrad Med J,2003,79:268-271.
  • 3Hall D.Controversies in heart failure.Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? Cardiol Clin,2001,19:597-603.
  • 4Bard RL,Bleske BE,Nicklas JM.Food:an unrecognized source of loop diuretic resistance.Pharmacotherapy,2004,24:630-637.
  • 5Jaski BE,Ha J, Denys BG,et al. Peripherally inserted veno-venous ultrafdtration for rapid treatment of volume overloaded patients.J Card Fail,2003,9:227-231.
  • 6Costanzo MR, Saltzberg M, O' Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coll Cardiol,2005,46:2047-2051.
  • 7Givertz MM,Massie BM,Fields TK,et al. The effects of KW-3902,an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.J Am Coll Cardiol,2007,50:1551-1560.
  • 8Cotter G,Dittrich HC,Weatherley BD,et al. The PROTECT pilot study:a randomized,placebo-controlled,dose-finding study of the adenosine Al receptor antagonist rolofylline in patients with acute heart failure and renal impairment.J Card Fail,2008,14: 631-640.
  • 9Paterna S,Di Pasquale P,Parrinello G,et al.Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.Eur J Heart Fail,2000,2:305-313.
  • 10Liu C,Liu G,Zhou C,et al.Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance.Can J Cardiol,2007,23:865-868.

共引文献51

同被引文献93

  • 1于安石,刘丽楠.冠脉介入术后患者血中B型钠利尿肽的动态变化及对心室重塑的影响[J].中国老年学杂志,2014,34(1):81-83. 被引量:4
  • 2王家宏,黄永麟.脑钠肽在心力衰竭诊治中的应用进展[J].中国实用内科杂志,2005,25(7):657-658. 被引量:21
  • 3沈潞华,赵树梅.老年人肾功能不全与心力衰竭[J].中华老年多器官疾病杂志,2007,6(6):379-381. 被引量:11
  • 4郝娟.老年心衰患者合并肾功能不全35例临床分析[J].健康大视野,2012.20(12):321--522.
  • 5Pan D,Li D.Role of ischemia-modified albumin in pa- tients with acute decompensated heart failure[J].Anatol J Cardiol,2015,15(8):618-619.
  • 6Vodovar N,S^ronde MF,Laribi S,et al.Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly In- hibit Circulating Neprilysin Activity in Heart Failure[J]. JACC Heart Fail,2015,3(8)..629-636.
  • 7Kelly JPjMentz RJ1Hasselblad V,et al Worsening heart fail- ure during hospitalization for acute heart failure:insights from the acute study of clinical effectiveness of nesiritide in decompensated heart failure(ASCEND-HF)[J].Am Heart J,2015,170(2):298-305.
  • 8Khazanie P,Heizer GM,Hasselblad V,et al.Pedictors of clinical outcomes in acute decompensated heart failure: acute study of clinical effectiveness of nesiritide in de- compensated heart failure outcome models[J].Am Heart J,2015,170(2):290-297.
  • 9Ibrahim N,Januzzi JL The potential role of natriuretic pep- tides and other biomarkers in heart failure diagnosis,prog- nosis and management[J],Expert Rev Cardiovasc Ther, 2015,13(9):1017-1030.
  • 10ARVD Velde,WC Meijers,RAD Boer.Biomarkers for risk prediction in acute decompensated heart failure[J]. Curr Heart Fail Rep,2014,11(3):246-259.

引证文献11

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部